 | • レポートコード：GIR-107A12261 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥508,080 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥762,120 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,016,160 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、腸内細菌科感染症薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。腸内細菌科感染症薬の種類別市場規模（ベータラクタム薬、カルバペネム薬、フルオロキノロン薬、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・腸内細菌科感染症薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Genentech、Nanotherapeutics、Novartis、Pfizer、Nymox Pharmaceutical、Sequoia Sciences、Phico Therapeutics、Cantab Biopharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：ベータラクタム薬、カルバペネム薬、フルオロキノロン薬、その他 ・用途別分析2016年-2026年：病院薬局、小売薬局、オンライン薬局 ・腸内細菌科感染症薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・腸内細菌科感染症薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・腸内細菌科感染症薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・腸内細菌科感染症薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・腸内細菌科感染症薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Enterobacteriaceae Infection Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Enterobacteriaceae Infection Drug size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Enterobacteriaceae Infection Drug market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Enterobacteriaceae Infection Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Beta-lactams Drugs
Carbapenems Drugs
Fluoroquinolones Drugs
Others
Market segment by Application, can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by players, this report covers
Genentech
Nanotherapeutics
Novartis
Pfizer
Nymox Pharmaceutical
Sequoia Sciences
Phico Therapeutics
Cantab Biopharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Enterobacteriaceae Infection Drug
1.2 Classification of Enterobacteriaceae Infection Drug by Type
1.2.1 Overview: Global Enterobacteriaceae Infection Drug Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Enterobacteriaceae Infection Drug Revenue Market Share by Type in 2020
1.2.3 Beta-lactams Drugs
1.2.4 Carbapenems Drugs
1.2.5 Fluoroquinolones Drugs
1.2.6 Others
1.3 Global Enterobacteriaceae Infection Drug Market by Application
1.3.1 Overview: Global Enterobacteriaceae Infection Drug Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Enterobacteriaceae Infection Drug Market Size & Forecast
1.5 Global Enterobacteriaceae Infection Drug Market Size and Forecast by Region
1.5.1 Global Enterobacteriaceae Infection Drug Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Enterobacteriaceae Infection Drug Market Size by Region, (2016-2021)
1.5.3 North America Enterobacteriaceae Infection Drug Market Size and Prospect (2016-2026)
1.5.4 Europe Enterobacteriaceae Infection Drug Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Enterobacteriaceae Infection Drug Market Size and Prospect (2016-2026)
1.5.6 South America Enterobacteriaceae Infection Drug Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Enterobacteriaceae Infection Drug Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Enterobacteriaceae Infection Drug Market Drivers
1.6.2 Enterobacteriaceae Infection Drug Market Restraints
1.6.3 Enterobacteriaceae Infection Drug Trends Analysis
2 Company Profiles
2.1 Genentech
2.1.1 Genentech Details
2.1.2 Genentech Major Business
2.1.3 Genentech Enterobacteriaceae Infection Drug Product and Solutions
2.1.4 Genentech Enterobacteriaceae Infection Drug Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Genentech Recent Developments and Future Plans
2.2 Nanotherapeutics
2.2.1 Nanotherapeutics Details
2.2.2 Nanotherapeutics Major Business
2.2.3 Nanotherapeutics Enterobacteriaceae Infection Drug Product and Solutions
2.2.4 Nanotherapeutics Enterobacteriaceae Infection Drug Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Nanotherapeutics Recent Developments and Future Plans
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Enterobacteriaceae Infection Drug Product and Solutions
2.3.4 Novartis Enterobacteriaceae Infection Drug Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Novartis Recent Developments and Future Plans
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Enterobacteriaceae Infection Drug Product and Solutions
2.4.4 Pfizer Enterobacteriaceae Infection Drug Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Pfizer Recent Developments and Future Plans
2.5 Nymox Pharmaceutical
2.5.1 Nymox Pharmaceutical Details
2.5.2 Nymox Pharmaceutical Major Business
2.5.3 Nymox Pharmaceutical Enterobacteriaceae Infection Drug Product and Solutions
2.5.4 Nymox Pharmaceutical Enterobacteriaceae Infection Drug Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Nymox Pharmaceutical Recent Developments and Future Plans
2.6 Sequoia Sciences
2.6.1 Sequoia Sciences Details
2.6.2 Sequoia Sciences Major Business
2.6.3 Sequoia Sciences Enterobacteriaceae Infection Drug Product and Solutions
2.6.4 Sequoia Sciences Enterobacteriaceae Infection Drug Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Sequoia Sciences Recent Developments and Future Plans
2.7 Phico Therapeutics
2.7.1 Phico Therapeutics Details
2.7.2 Phico Therapeutics Major Business
2.7.3 Phico Therapeutics Enterobacteriaceae Infection Drug Product and Solutions
2.7.4 Phico Therapeutics Enterobacteriaceae Infection Drug Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Phico Therapeutics Recent Developments and Future Plans
2.8 Cantab Biopharmaceuticals
2.8.1 Cantab Biopharmaceuticals Details
2.8.2 Cantab Biopharmaceuticals Major Business
2.8.3 Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Product and Solutions
2.8.4 Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Cantab Biopharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Enterobacteriaceae Infection Drug Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Enterobacteriaceae Infection Drug Players Market Share
3.2.2 Top 10 Enterobacteriaceae Infection Drug Players Market Share
3.2.3 Market Competition Trend
3.3 Enterobacteriaceae Infection Drug Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Enterobacteriaceae Infection Drug Revenue and Market Share by Type (2016-2021)
4.2 Global Enterobacteriaceae Infection Drug Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Enterobacteriaceae Infection Drug Revenue Market Share by Application (2016-2021)
5.2 Enterobacteriaceae Infection Drug Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Enterobacteriaceae Infection Drug Revenue by Type (2016-2026)
6.2 North America Enterobacteriaceae Infection Drug Revenue by Application (2016-2026)
6.3 North America Enterobacteriaceae Infection Drug Market Size by Country
6.3.1 North America Enterobacteriaceae Infection Drug Revenue by Country (2016-2026)
6.3.2 United States Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
6.3.3 Canada Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
6.3.4 Mexico Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Enterobacteriaceae Infection Drug Revenue by Type (2016-2026)
7.2 Europe Enterobacteriaceae Infection Drug Revenue by Application (2016-2026)
7.3 Europe Enterobacteriaceae Infection Drug Market Size by Country
7.3.1 Europe Enterobacteriaceae Infection Drug Revenue by Country (2016-2026)
7.3.2 Germany Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
7.3.3 France Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
7.3.5 Russia Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
7.3.6 Italy Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Enterobacteriaceae Infection Drug Revenue by Type (2016-2026)
8.2 Asia-Pacific Enterobacteriaceae Infection Drug Revenue by Application (2016-2026)
8.3 Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Region
8.3.1 Asia-Pacific Enterobacteriaceae Infection Drug Revenue by Region (2016-2026)
8.3.2 China Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
8.3.3 Japan Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
8.3.4 South Korea Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
8.3.5 India Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
8.3.7 Australia Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Enterobacteriaceae Infection Drug Revenue by Type (2016-2026)
9.2 South America Enterobacteriaceae Infection Drug Revenue by Application (2016-2026)
9.3 South America Enterobacteriaceae Infection Drug Market Size by Country
9.3.1 South America Enterobacteriaceae Infection Drug Revenue by Country (2016-2026)
9.3.2 Brazil Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
9.3.3 Argentina Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Enterobacteriaceae Infection Drug Revenue by Type (2016-2026)
10.2 Middle East & Africa Enterobacteriaceae Infection Drug Revenue by Application (2016-2026)
10.3 Middle East & Africa Enterobacteriaceae Infection Drug Market Size by Country
10.3.1 Middle East & Africa Enterobacteriaceae Infection Drug Revenue by Country (2016-2026)
10.3.2 Turkey Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
10.3.4 UAE Enterobacteriaceae Infection Drug Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Enterobacteriaceae Infection Drug Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Enterobacteriaceae Infection Drug Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Enterobacteriaceae Infection Drug Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Enterobacteriaceae Infection Drug Revenue (USD Million) by Region (2016-2021)
Table 5. Global Enterobacteriaceae Infection Drug Revenue Market Share by Region (2021-2026)
Table 6. Genentech Corporate Information, Head Office, and Major Competitors
Table 7. Genentech Major Business
Table 8. Genentech Enterobacteriaceae Infection Drug Product and Solutions
Table 9. Genentech Enterobacteriaceae Infection Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Nanotherapeutics Corporate Information, Head Office, and Major Competitors
Table 11. Nanotherapeutics Major Business
Table 12. Nanotherapeutics Enterobacteriaceae Infection Drug Product and Solutions
Table 13. Nanotherapeutics Enterobacteriaceae Infection Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Novartis Corporate Information, Head Office, and Major Competitors
Table 15. Novartis Major Business
Table 16. Novartis Enterobacteriaceae Infection Drug Product and Solutions
Table 17. Novartis Enterobacteriaceae Infection Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Pfizer Corporate Information, Head Office, and Major Competitors
Table 19. Pfizer Major Business
Table 20. Pfizer Enterobacteriaceae Infection Drug Product and Solutions
Table 21. Pfizer Enterobacteriaceae Infection Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Nymox Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 23. Nymox Pharmaceutical Major Business
Table 24. Nymox Pharmaceutical Enterobacteriaceae Infection Drug Product and Solutions
Table 25. Nymox Pharmaceutical Enterobacteriaceae Infection Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Sequoia Sciences Corporate Information, Head Office, and Major Competitors
Table 27. Sequoia Sciences Major Business
Table 28. Sequoia Sciences Enterobacteriaceae Infection Drug Product and Solutions
Table 29. Sequoia Sciences Enterobacteriaceae Infection Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Phico Therapeutics Corporate Information, Head Office, and Major Competitors
Table 31. Phico Therapeutics Major Business
Table 32. Phico Therapeutics Enterobacteriaceae Infection Drug Product and Solutions
Table 33. Phico Therapeutics Enterobacteriaceae Infection Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Cantab Biopharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 35. Cantab Biopharmaceuticals Major Business
Table 36. Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Product and Solutions
Table 37. Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Global Enterobacteriaceae Infection Drug Revenue (USD Million) by Players (2019-2021)
Table 39. Global Enterobacteriaceae Infection Drug Revenue Share by Players (2019-2021)
Table 40. Breakdown of Enterobacteriaceae Infection Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. Enterobacteriaceae Infection Drug Players Head Office, Products and Services Provided
Table 42. Enterobacteriaceae Infection Drug Mergers & Acquisitions in the Past Five Years
Table 43. Enterobacteriaceae Infection Drug New Entrants and Expansion Plans
Table 44. Global Enterobacteriaceae Infection Drug Revenue (USD Million) by Type (2016-2021)
Table 45. Global Enterobacteriaceae Infection Drug Revenue Share by Type (2016-2021)
Table 46. Global Enterobacteriaceae Infection Drug Revenue Forecast by Type (2021-2026)
Table 47. Global Enterobacteriaceae Infection Drug Revenue by Application (2016-2021)
Table 48. Global Enterobacteriaceae Infection Drug Revenue Forecast by Application (2021-2026)
Table 49. North America Enterobacteriaceae Infection Drug Revenue by Type (2016-2021) & (USD Million)
Table 50. North America Enterobacteriaceae Infection Drug Revenue by Type (2021-2026) & (USD Million)
Table 51. North America Enterobacteriaceae Infection Drug Revenue by Application (2016-2021) & (USD Million)
Table 52. North America Enterobacteriaceae Infection Drug Revenue by Application (2021-2026) & (USD Million)
Table 53. North America Enterobacteriaceae Infection Drug Revenue by Country (2016-2021) & (USD Million)
Table 54. North America Enterobacteriaceae Infection Drug Revenue by Country (2021-2026) & (USD Million)
Table 55. Europe Enterobacteriaceae Infection Drug Revenue by Type (2016-2021) & (USD Million)
Table 56. Europe Enterobacteriaceae Infection Drug Revenue by Type (2021-2026) & (USD Million)
Table 57. Europe Enterobacteriaceae Infection Drug Revenue by Application (2016-2021) & (USD Million)
Table 58. Europe Enterobacteriaceae Infection Drug Revenue by Application (2021-2026) & (USD Million)
Table 59. Europe Enterobacteriaceae Infection Drug Revenue by Country (2016-2021) & (USD Million)
Table 60. Europe Enterobacteriaceae Infection Drug Revenue by Country (2021-2026) & (USD Million)
Table 61. Asia-Pacific Enterobacteriaceae Infection Drug Revenue by Type (2016-2021) & (USD Million)
Table 62. Asia-Pacific Enterobacteriaceae Infection Drug Revenue by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific Enterobacteriaceae Infection Drug Revenue by Application (2016-2021) & (USD Million)
Table 64. Asia-Pacific Enterobacteriaceae Infection Drug Revenue by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific Enterobacteriaceae Infection Drug Revenue by Region (2016-2021) & (USD Million)
Table 66. Asia-Pacific Enterobacteriaceae Infection Drug Revenue by Region (2021-2026) & (USD Million)
Table 67. South America Enterobacteriaceae Infection Drug Revenue by Type (2016-2021) & (USD Million)
Table 68. South America Enterobacteriaceae Infection Drug Revenue by Type (2021-2026) & (USD Million)
Table 69. South America Enterobacteriaceae Infection Drug Revenue by Application (2016-2021) & (USD Million)
Table 70. South America Enterobacteriaceae Infection Drug Revenue by Application (2021-2026) & (USD Million)
Table 71. South America Enterobacteriaceae Infection Drug Revenue by Country (2016-2021) & (USD Million)
Table 72. South America Enterobacteriaceae Infection Drug Revenue by Country (2021-2026) & (USD Million)
Table 73. Middle East & Africa Enterobacteriaceae Infection Drug Revenue by Type (2016-2021) & (USD Million)
Table 74. Middle East & Africa Enterobacteriaceae Infection Drug Revenue by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa Enterobacteriaceae Infection Drug Revenue by Application (2016-2021) & (USD Million)
Table 76. Middle East & Africa Enterobacteriaceae Infection Drug Revenue by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa Enterobacteriaceae Infection Drug Revenue by Country (2016-2021) & (USD Million)
Table 78. Middle East & Africa Enterobacteriaceae Infection Drug Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Enterobacteriaceae Infection Drug Picture
Figure 2. Global Enterobacteriaceae Infection Drug Revenue Market Share by Type in 2020
Figure 3. Beta-lactams Drugs
Figure 4. Carbapenems Drugs
Figure 5. Fluoroquinolones Drugs
Figure 6. Others
Figure 7. Enterobacteriaceae Infection Drug Revenue Market Share by Application in 2020
Figure 8. Hospital Pharmacies Picture
Figure 9. Retail Pharmacies Picture
Figure 10. Online Pharmacies Picture
Figure 11. Global Enterobacteriaceae Infection Drug Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Enterobacteriaceae Infection Drug Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Enterobacteriaceae Infection Drug Revenue Market Share by Region (2016-2026)
Figure 14. Global Enterobacteriaceae Infection Drug Revenue Market Share by Region in 2020
Figure 15. North America Enterobacteriaceae Infection Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Enterobacteriaceae Infection Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Enterobacteriaceae Infection Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Enterobacteriaceae Infection Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Enterobacteriaceae Infection Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Enterobacteriaceae Infection Drug Market Drivers
Figure 21. Enterobacteriaceae Infection Drug Market Restraints
Figure 22. Enterobacteriaceae Infection Drug Market Trends
Figure 23. Genentech Recent Developments and Future Plans
Figure 24. Nanotherapeutics Recent Developments and Future Plans
Figure 25. Novartis Recent Developments and Future Plans
Figure 26. Pfizer Recent Developments and Future Plans
Figure 27. Nymox Pharmaceutical Recent Developments and Future Plans
Figure 28. Sequoia Sciences Recent Developments and Future Plans
Figure 29. Phico Therapeutics Recent Developments and Future Plans
Figure 30. Cantab Biopharmaceuticals Recent Developments and Future Plans
Figure 31. Global Enterobacteriaceae Infection Drug Revenue Share by Players in 2020
Figure 32. Enterobacteriaceae Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 33. Global Top 3 Players Enterobacteriaceae Infection Drug Revenue Market Share in 2020
Figure 34. Global Top 10 Players Enterobacteriaceae Infection Drug Revenue Market Share in 2020
Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 36. Global Enterobacteriaceae Infection Drug Revenue Share by Type in 2020
Figure 37. Global Enterobacteriaceae Infection Drug Market Share Forecast by Type (2021-2026)
Figure 38. Global Enterobacteriaceae Infection Drug Revenue Share by Application in 2020
Figure 39. Global Enterobacteriaceae Infection Drug Market Share Forecast by Application (2021-2026)
Figure 40. North America Enterobacteriaceae Infection Drug Sales Market Share by Type (2016-2026)
Figure 41. North America Enterobacteriaceae Infection Drug Sales Market Share by Application (2016-2026)
Figure 42. North America Enterobacteriaceae Infection Drug Revenue Market Share by Country (2016-2026)
Figure 43. United States Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Enterobacteriaceae Infection Drug Sales Market Share by Type (2016-2026)
Figure 47. Europe Enterobacteriaceae Infection Drug Sales Market Share by Application (2016-2026)
Figure 48. Europe Enterobacteriaceae Infection Drug Revenue Market Share by Country (2016-2026)
Figure 49. Germany Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Enterobacteriaceae Infection Drug Sales Market Share by Type (2016-2026)
Figure 55. Asia-Pacific Enterobacteriaceae Infection Drug Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Enterobacteriaceae Infection Drug Revenue Market Share by Region (2016-2026)
Figure 57. China Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Japan Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. South Korea Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. India Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Southeast Asia Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Australia Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South America Enterobacteriaceae Infection Drug Sales Market Share by Type (2016-2026)
Figure 64. South America Enterobacteriaceae Infection Drug Sales Market Share by Application (2016-2026)
Figure 65. South America Enterobacteriaceae Infection Drug Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East and Africa Enterobacteriaceae Infection Drug Sales Market Share by Type (2016-2026)
Figure 69. Middle East and Africa Enterobacteriaceae Infection Drug Sales Market Share by Application (2016-2026)
Figure 70. Middle East and Africa Enterobacteriaceae Infection Drug Revenue Market Share by Country (2016-2026)
Figure 71. Turkey Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Saudi Arabia Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. UAE Enterobacteriaceae Infection Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Methodology
Figure 75. Research Process and Data Source
世界のCディフィシル感染症治療薬市場 2021：企業別、地域別、種類・用途別 The C Difficile Infection Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…- 世界のサイトメガロウイルス（HHV-5）感染症治療薬市場 2021：企業別、地域別、種類・用途別 The Cytomegalovirus（HHV-5）Infection Therapeutic Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain o…
- 世界のグラム陽性菌感染症薬市場予測（～2024年）：企業別、地域別、種類・用途別 Gram-positive bacteria are those that are stained dark blue or violet by Gram staining. They are a major class of bacteria that cause various infections in humans. Scope of the Report: The global Gram-positive Bacterial Infection Drugs market is valued at xx million USD in 2018 and is expected to re…
- サイトメガロウイルス（HHV-5）感染症治療薬の世界市場 2019年版：種類別（経口薬、注射）、用途別（病院、診療所、その他） Description Scope of the Report: The global Cytomegalovirus（HHV-5）Infection Therapeutic Drugs market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in f…
- 世界の眼感染症薬市場予測（～2024年）：メーカー別、地域別、種類・用途別 Scope of the Report: The worldwide market for Eye Infection Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Eye Infection Drugs…